CVS Has Beaten Estimates for Five Straight Quarters. The Stock Keeps Falling Anyway.

Key Stats for CVS Stock

• 52-Week Range: $69.51 to $110.68
• Street Mean Target: $116.04
• Market Cap: ~$123.7B
• LTM Net Debt/EBITDA: 3.17x
• Forward 2-Yr EPS CAGR: ~12%
• Dividend Yield: 2.8%

Value your favorite stocks like CVS with 5 years of analysts’ forecasts using TIKR’s new Valuation Model (It’s free) >>>

CVS Keeps Beating Estimates. The Market Keeps Shrugging.

CVS Health (CVS) is one of the more unusual situations in large-cap healthcare right now: a company that has beaten consensus estimates on revenue, EBITDA, and adjusted EPS in each of the past five quarters, raised full-year guidance twice in 2026, and still seen its stock fall on earnings day twice in that same stretch. Understanding why requires understanding what CVS actually is and why the market has struggled to assign it a premium.

CVS operates three interconnected businesses. Its pharmacy and consumer wellness segment is one of the largest retail pharmacy networks in the country. Its health services arm, Caremark, runs pharmacy benefit management, meaning it negotiates drug pricing between insurers and drug manufacturers on behalf of tens of millions of plan members.

And its insurance business, Aetna, provides medical coverage to roughly 25 million people through commercial, Medicare Advantage, and Medicaid plans.

The ambition behind assembling all three was vertical integration: a health company that could control the full patient journey from insurance enrollment through prescription fulfillment. The execution, particularly at Aetna, has been the source of most of the pain.

The beat streak is consistent and accelerating. In Q2 2026, CVS reported revenues of $106.1 billion against estimates of around $100 billion, a 6% beat.

Adjusted EPS of $2.58 came in roughly 39% above what analysts had modeled. Cash flow from operations reached $6.3 billion in the quarter, more than double the consensus estimate.

Management raised full-year adjusted EPS guidance to $7.90 to $8.10 and lifted cash flow from operations guidance to at least $11.5 billion. CEO David Joyner said the results demonstrated “strong execution across our businesses.” The stock fell nearly 3% on the day of the report.

See historical and forward estimates for CVS stock (It’s free!) >>>

The EBITDA Picture Shows the Recovery, and the Seasonality That Confuses It

One reason the market struggles with CVS is the pronounced quarterly seasonality in its financials, which makes individual quarters difficult to interpret without context.

Quarterly EBITDA troughed at $3.3 billion in Q4 2025 before surging to $5.8 billion in Q1 2026 and $5.9 billion in Q2 2026.

Estimates show a predictable pullback to around $4.2 billion in Q3 and $3.6 billion in Q4 2026, driven by insurance enrollment cycles and the timing of pharmacy benefit contracts, before recovering again in early 2027. This pattern repeats annually and is structural, not a sign of deterioration.

On a trailing basis, the business is generating roughly $19 to $20 billion in annual EBITDA, and forward estimates project that figure will grow about 10% annually over the next two years as Aetna’s medical benefit ratio stabilizes and the pharmacy services business continues to expand.

Aetna also launched its second-generation AI claims processing tool in Q2, which reduces review time by more than 20% for complex claims, a margin lever that should compound quietly over multiple quarters.

See how CVS performs against its peers in TIKR (It’s free!) >>>

What the Valuation Model Says About a Business the Market Has Ignored for a Decade

TIKR’s valuation model targets around $133 for CVS stock in the mid case, implying roughly a 38% total return over the next four-plus years at an annualized rate of around 8% per year.

The high case, which assumes stronger execution on Aetna margin recovery and continued pharmacy services growth, reaches an annualized return closer to 11%.

The honest context here is that CVS has been a poor long-term compounder. The 10-year annualized return in the historical data is essentially flat at 0.4%, reflecting a decade of acquisition integration costs, Aetna medical cost pressures, and a pharmacy reimbursement environment that has squeezed margins.

The model’s mid-case assumptions of 4% revenue growth and 8.9% EPS compounding are not heroic, but they do require Aetna to stop being a drag.

The Street mean target of around $116 implies roughly 20% upside from current levels, and at 12x forward earnings with a 2.8% dividend, the valuation leaves room for multiple expansion if the execution holds.

Should You Buy CVS Stock?

The bull case is grounded in valuation and cash flow. A business generating $11.5 billion or more in annual operating cash flow, trading at 12x forward earnings, with a covered dividend and a clear path to debt reduction, is not obviously expensive.

Five consecutive quarters of beats suggest the worst of the Aetna medical cost issues may be behind the company, and the guidance raise gives management some credibility on the recovery narrative.

The bear case is harder to dismiss given the history. CVS has said its turnaround is on track for years. The stock has barely moved over a decade, and the insurance business remains exposed to medical cost inflation that can deteriorate quickly.

Investors who bought the “cheap healthcare conglomerate” thesis at $80 are only modestly ahead, which is a reminder that valuation alone rarely drives a re-rating without a catalyst the market believes in.

See analysts’ growth forecasts and price targets for CVS stock (It’s free!) >>>

Looking for New Opportunities?

• See which stocks billionaire investors are buying to follow the smart money.
• Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
• The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.

Disclaimer:

Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!